What is the
PROSPER Clinical
Trial?
The PROSPER Clinical Trial is a global
Phase 3 clinical research trial that will in-
clude about 1500 participants. The trial will
test the effects of an oral investigational drug
called enzalutamide in men with non-
metastatic prostate cancer that continues to
progress despite hormonal therapy. The pur-
pose of the PROSPER Clinical Trial is to
compare how enzalutamide works when com-
bined with standard treatment vs. the stan-
dard treatment only.
You may qualify for the
PROSPER Clinical Trial
Join the PROSPER Clinical
Trial
Do you or does someone you care about have a
PSA that is continuously rising? If so, please
consider taking part in the PROSPER Clinical
Trial for patients with prostate cancer that has
not spread beyond the prostate, but has pro-
gressed on hormonal therapy. In the PROS-
PER trial, patients will have a two out of three
chance of being randomized to receive enzalu-
tamide or a one in three chance of receiving
placebo. All patients will receive standard
treatment in addition to their respective drug/
placebo assignment.
Learn more
Ask your doctor or visit www.clinicaltrials.gov
for more information (clinicaltrials.gov; Identifier
NCT02003924)
Is your PSA rising?
Is your cancer limited to your
prostate?
Is your cancer causing no
pain?
What should you expect
if you join the PROSPER
Clinical Trial?
You will be asked to take your study medica-
tion capsules orally once a day. You will con-
tinue to take medication that lower testoster-
one levels unless you have had an orchiec-
tomy (had your tes-
ticles removed).
Two out of three
trial participants
will receive enzalu-
tamide, the investi-
gational drug being
studied. One in
three of the participants will receive placebo.
You will be seen at the study doctor’s office
one month after entering the study, 3 months
later, and then every 4 months thereafter
while you are taking the prostate cancer trial
medication on a daily basis. At each visit, the
doctor will assess how the treatment is work-
ing and whether you have any side effects. In
addition to the treatment provided by the
study doctor, you will continue to receive
care from your current medical team.
PROSPER Clinical Trial
site locations:
The PROSPER Clinical Trial is taking place
at many sites worldwide.
If you believe that you or someone you care
about meets the PROSPER Clinical Trial en-
try requirements, please speak with your doc-
tor or visit www.clinicaltrials.gov (Identifier:
NCT02003924) for a list of trial site locations.
Who can join the
PROSPER Clinical Trial?
Men whose prostate cancer fits
this description may be able to
join the PROSPER Trial:
• Your cancer has not spread beyond
the prostate
Your PSA is rising despite treat-
ment with hormonal therapy
• Your cancer causes no pain
Other inclusion/exclusion criteria
may apply
V2.0 03 Dec 2014